Dyadic International (DYAI) Cash from Investing Activities Growth (1y) (2019 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Cash from Investing Activities Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn | -46.27% |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn | -388.99% |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn | 90.55% |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 91.53% |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn | -41.67% |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn | -157.08% |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn | -6,635.44% |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 18.24 Mn | 10.27 Mn | - | 162.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 162.64% |
| Dec 31, 2025 | -62.94% |
| Sep 30, 2025 | 880.18% |
| Jun 30, 2025 | 61.11% |
| Mar 31, 2025 | 173.61% |
| Dec 31, 2024 | 3,598.76% |
| Sep 30, 2024 | -100.34% |
| Jun 30, 2024 | -320.55% |
| Mar 31, 2024 | -123.67% |
| Dec 31, 2023 | -94.47% |
| Sep 30, 2023 | 369.28% |
| Jun 30, 2023 | 196.95% |
| Mar 31, 2023 | 631.29% |
| Dec 31, 2022 | -86.27% |
| Sep 30, 2022 | -132.70% |
| Jun 30, 2022 | -100.02% |
| Mar 31, 2022 | 99.99% |
| Dec 31, 2021 | 11,677.33% |
| Sep 30, 2021 | -65.04% |
| Jun 30, 2021 | 64,631.33% |